SCHEDULE: Yarrow Bioscience Stakeholder Update

AI Biotechnology LLC and affiliated entities report a 6.02% stake in Yarrow Bioscience, Inc. following a merger and stock split.

Summary

• AI Biotechnology LLC, along with Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik, have filed an amendment to their Schedule 13D.
• This filing updates their beneficial ownership in Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.).
• The reporting persons collectively hold 22,331 shares of common stock and warrants to purchase an additional 155,849 shares.
• This represents a 6.02% ownership stake in the company.
• The update follows a merger and a 1-for-50 reverse stock split that became effective on July 24, 2026.
• The merger involved VYNE Therapeutics Inc. and Yarrow Bioscience, Inc. (Pre-Merger Yarrow).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on completed corporate actions and current ownership stakes without new financial performance data or future guidance.

Positives

• The reporting persons maintain a significant stake (6.02%) in Yarrow Bioscience, Inc., indicating continued investment interest.
• The completion of the merger and reverse stock split are key corporate actions that have been successfully executed.

Negatives

• The reverse stock split significantly reduced the number of shares held by AI Biotechnology from 1,116,585 to 22,331.
• Fractional shares resulting from the reverse stock split were converted to cash payments, potentially reducing the direct shareholding for some.

Risks

• The exercise price and number of shares issuable upon exercise of warrants were adjusted due to the reverse stock split, which could impact future equity gains.
• The filing does not detail the specific cash payment received for fractional shares, which could represent a minor loss of potential upside.

Future Outlook

The filing primarily reports on past events (merger, stock split) and current ownership stakes. No specific forward-looking financial guidance or strategic outlook for Yarrow Bioscience, Inc. is provided within this amendment.

Management Comments

• The Schedule 13D was originally filed with respect to VYNE Therapeutics Inc., which changed its name to Yarrow Bioscience, Inc. upon the consummation of the Merger.
• Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.

Industry Context

StockSavvy.ai notes that this filing reflects significant corporate restructuring for Yarrow Bioscience, Inc., including a merger and a reverse stock split. Such actions are often undertaken by biotechnology companies to meet exchange listing requirements, consolidate share structures, or prepare for future financing or strategic initiatives.

Comparison to Industry Standards

• Reverse stock splits are common in the biotechnology sector, particularly for companies aiming to increase their per-share stock price to meet minimum bid requirements for major exchanges like Nasdaq. For example, many small-cap biotech firms undertake such splits when their share price falls below $1.
• Mergers and acquisitions are also prevalent, allowing companies to combine resources, gain access to new technologies, or achieve economies of scale. The specific merger details here are unique to Yarrow Bioscience and its former entity VYNE Therapeutics.

Stakeholder Impact

• Shareholders: The reverse stock split reduces the number of shares outstanding, potentially increasing the share price but also diluting ownership percentage for existing holders if not proportionally reinvested. Cash payments for fractional shares represent a minor divestment.
• Warrant Holders: The terms of the warrants have been adjusted, impacting the number of shares issuable and potentially the exercise price, which needs careful review.
• Management/Board: The merger and name change indicate significant strategic shifts and potential integration efforts.

Next Steps

• The reporting persons will continue to monitor the Issuer's business and may, from time to time, acquire or dispose of additional securities of the Issuer.
• Future actions regarding the exercise of warrants will depend on market conditions and the company's performance.

Key Dates

Keywords

Yarrow Bioscience, Schedule 13D, Merger, Reverse Stock Split, Beneficial Ownership, AI Biotechnology, Access Industries, Warrants